Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Monopar Therapeutics Inc
(NQ:
MNPR
)
2.430
-0.010 (-0.41%)
Streaming Delayed Price
Updated: 3:58 PM EDT, Sep 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Monopar Therapeutics Inc
< Previous
1
2
Next >
Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments
May 11, 2023
Camsirubicin Phase 1b DoseEscalation Trial Enrolling 5th DoseLevel Cohort (650 mg/m2) MNPR-101 RIT Shows Promising Imaging and Therapeutic Preclinical Study Results
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar to Present at the Jefferies Radiopharma Innovation Summit
March 28, 2023
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis
March 27, 2023
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments
March 23, 2023
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar to Present at the 35th Annual Roth Conference
March 07, 2023
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials
February 27, 2023
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin
February 14, 2023
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT
January 26, 2023
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2
January 18, 2023
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration
December 12, 2022
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial
November 16, 2022
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments
November 10, 2022
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202
October 27, 2022
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting
October 19, 2022
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting
October 12, 2022
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis
October 05, 2022
Interim Analysis Planned for Q1 2023
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar to Present at Roth Inaugural Healthcare Opportunities Conference
September 28, 2022
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.